NORTHBRIDGE, Mass. , Dec. 24, 2020 /PRNewswire/ -- Interscope, Inc. announced today the receipt of FDA de novo clearance to market its EndoRotor® System in the United States for direct ...
Today, the U.S. Food and Drug Administration authorized marketing of the EndoRotor System to resect (cut out) and remove necrotic (dead) tissue for patients with walled-off pancreatic necrosis (WOPN), ...
The US Food and Drug Administration (FDA) has approved the EndoRotor System (Interscope, Inc) for removal of necrotic tissue in patients with walled-off pancreatic necrosis (WOPN). "This device has ...
The U.S. FDA granted de novo marketing authorization to Interscope Inc.’s Endorotor system for direct endoscopic necrosectomy (DEN) of walled-off pancreatic necrosis, giving the specialty device a ...
SILVER SPRING, Md., Dec. 23, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration authorized marketing of the EndoRotor System to resect (cut out) and remove necrotic (dead) tissue for ...
- Interscope, Inc. and Micro-Tech Endoscopy signed a partnership agreement focused on the distribution of Interscope's unique EndoRotor System for gastroenterology. - EndoRotor is now the first and ...
The U.S. FDA granted de novo marketing authorization to Interscope Inc.’s Endorotor system for direct endoscopic necrosectomy (DEN) of walled-off pancreatic necrosis, giving the specialty device a ...
Interscope, Inc. announced the receipt of FDA de novo clearance to market its EndoRotor System in the United States for direct endoscopic necrosectomy (DEN), a minimally invasive treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results